medigraphic.com
Colegio de Medicina Interna de México.

2022, Number 4

<< Back Next >>

Med Int Mex 2022; 38 (4)

Characterization of patients with beta-thalassemia in a high complexity institution, Medellin, Colombia

Martínez-Sánchez LM, Carvajal-Alzate M, Roldán-Tabares MD, Vergara-Yanez D

Language: Spanish
References: 24
Page: 783-790
PDF size: 210.93 Kb.


ABSTRACT

Objective: To characterize the patients with beta-thalassemia treated in a highly complex institution.
Materials and Methods: Descriptive observational study, which included patients younger than 17 years with a diagnosis of beta-thalassemia who had a characteristic clinical profile and laboratory findings. A non-probabilistic sampling of consecutive cases was carried out.
Results: Thirty-five medical records were reviewed, 21 were male, whose average age of diagnosis was 6.7 years. The most common clinical finding was anemia in 29/35 and the most common complications were cardiac in 6/35. Regarding treatment, 9/35 were dependent on transfusions, 3/35 required transplantation and 4/35 required splenectomy. The paraclinical studies most used in the diagnosis were hemogram (34/35) and protein electrophoresis (24/35). Out of the 35 patients, 10 had hypochromic macrocytic anemia, 2 normochromic microcytic anemia and one normochromic macrocytic anemia.
Conclusions: Beta-thalassemia occurs mainly in early childhood; it is expressed in clinical phenotypes grouped according to the need or not of transfusions; the latter was the most prevalent. Macrocytic hypochromic anemia was the main clinical finding, which was addressed with medical management rather than with invasive therapies. Due to the size of the sample, more studies are required to enrich the clinical characterization of this disease.


REFERENCES

  1. Rosenfeld LG, Bacal NS, Cuder MAM, Silva AGD, MachadoÍE, Pereira CA, et al. Prevalence of hemoglobinopathiesin the Brazilian adult population: National Health Survey 2014-2015. Rev Bras Epidemiol 2019; 22Suppl 02 (Suppl 02):E190007.SUPL.2. doi: 10.1590/1980 549720190007.supl.2.

  2. Sharma A, Easow M, Puri L. Splenectomy for people withthalassaemia major or intermedia. Cochrane DatabaseSyst Rev 2019; 9: CD010517. doi: 10.1002/14651858.CD010517.pub3.

  3. Jalil T, Yousafzai YM, Rashid I, Ahmed S, Ali A, Fatima S, etal. Mutational analysis of beta thalassaemia by multiplexARMS-PCR In Khyber Pakhtunkhwa, Pakistan. J Ayub MedColl Abbottabad 2019; 31 (1): 98-103.

  4. Martin A, Thompson AA. Thalassemias. Pediatr Clin NorthAm 2013; 60 (6): 1383-91. DOI: 10.1016/j.pcl.2013.08.008.

  5. Lazarte S, Leri M, Jiménez C, Haro A, Burgos M, Issé B.Resistencia osmótica eritrocitaria en el diagnóstico deanemias hereditarias en Tucumán, Argentina. Acta BioquímClín Latinoam 2012; 46 (4): 645-53.

  6. Motta I, Mancarella M, Marcon A, Vicenzi M, Cappellini MD.Management of age-associated medical complications inpatients with β-thalassemia. Expert Rev Hematol 2019; 12:1-10. doi: 10.1080/17474086.2020.1686354.

  7. Bollig C, Schell LK, Rücker G, Allert R, Motschall E, NiemeyerCM, et al. Deferasirox for managing iron overload in peoplewith thalassaemia. Cochrane Database Syst Rev 2017; 8:CD007476. DOI:10.1002/14651858.

  8. Silva JR, Malambo D, Silva DF, Fals E, Fals O, Rey J. Tamizajede Hemoglobinopatías en una Muestra de la PoblaciónInfantil de Cartagena. Pediatría 1998; 33 (2): 86-9.

  9. Echeverry SJ, Colmenares CC, Yepes ZX, Martínez O, IsazaMA. Hemoglobinopathy detection through an institutional neonatal screening program in Colombia. J BrasPatol Med Lab 2016; 52 (5): 299-306. DOI: 10.5935 16762444.20160050.

  10. Mustafa I, Firdous N, Shebl FM, Shi Z, Saeed M, Zahir Z,Zayed H. Genetic epidemiology of beta-thalassemia inthe Maldives: 23 years of a beta-thalassemia screeningprogram. Gene 2020; 741: 144544. DOI: 10.1016/j.gene.2020.144544.

  11. Lazarte SS, Mónaco ME, Haro AC, Jiménez CL, Ledesma Achem ME, Issé BA. Molecular characterizationand phenotypical study of β-thalassemia in Tucumán,Argentina. Hemoglobin 2014; 38 (6): 394-401. DOI:10.3109/03630269.2014.968784.

  12. Hong CR, Kang HJ, Lee JW, Kim H, Kim NH, Park KD, ParkJD, Seong MW, Park SS, Shin HY, Ahn HS. Clinical characteristics of pediatric thalassemia in Korea: a single instituteexperience. J Korean Med Sci 2013; 28 (11): 1645-9. DOI:10.3346/jkms.2013.28.11.1645.

  13. Hassan T, Zakaria M, Fathy M, Arafa M, El Gebaly S, EmamA, Abdel Wahab A, Shehab M, Salah H, Malek M, El GerbyK. Association between genotype and disease complications in Egyptian patients with beta thalassemia: A Crosssectional study. Sci Rep 2018; 8 (1): 17730. DOI: 10.1038/s41598-018-36175-9.

  14. Mettananda S, Pathiraja H, Peiris R, Wickramarathne N,Bandara D, de Silva U, et al. Blood transfusion therapy forβ-thalassemia major and hemoglobin E β-thalassemia:Adequacy, trends, and determinants in Sri Lanka. Pediatr Blood Cancer 2019; 66 (5): e27643. doi: 10.1002/pbc.27643.

  15. Lal A, Wong TE, Andrews J, Balasa VV, Chung JH, ForesterCM, et al. Transfusion practices and complications inthalassemia. Transfusion 2018; 58 (12): 2826-2835. doi:10.1111/trf.14875.

  16. Merchant RH, Shah AR, Ahmad J, Karnik A, Rai N. Postsplenectomy outcome in β-thalassemia. Indian J Pediatr2015; 82 (12): 1097-100. doi: 10.1007/s12098-015-1792-5.

  17. Ghavamzadeh A, Kasaeian A, Rostami T, Kiumarsi A. Comparable outcomes of allogeneic peripheral blood versus bonemarrow hematopoietic stem cell transplantation in majorthalassemia: A multivariate long-term cohort analysis.Biol Blood Marrow Transplant 2019; 25 (2): 307-312. doi:10.1016/j.bbmt.2018.09.026.

  18. Pernudy-Ubau A, Campos-Gómez V, Rojas-Vanegas L, Ramírez M, Mejía-Baltodano G, Rodríguez-Romero W. Identificación de β-talasemia en anemias microcíticas hipocrómicasrefractarias al tratamiento con hierro en Nicaragua. ActaMéd Costarric 2018; 60 (4): 162-66.

  19. Nillakupt K, Nathalang O, Arnutti P, Jindadamrongwech S,Boonsiri T, Panichkul S et al. Prevalence and hematological parameters of thalassemia in Tha Kradarn Subdistrict Chachoengsao Province, Thailand. J Med Assoc Thai 2012; 95: 124-32.

  20. Chamchoi A, Srihirun S, Paiboonsukwong K, SriwantanaT, Kongkaew P, Fucharoen S, et al. Hemoglobin-boundplatelets correlate with the increased platelet activity inhemoglobin E/β-thalassemia. Int J Lab Hematol 2020; 42(5): 518-525. doi: 10.1111/ijlh.13260.

  21. Khawaji MM, Hazzazi AA, Ageeli MH, Mawkili YH, DarbashiAH, Abo Kathiyah AMA, et al. Clinical and hematologicalfeatures among β-thalassemia major patients in Jazanregion: A hospital-based study. J Family Med Prim Care2020; 9 (1): 412-417. doi: 10.4103/jfmpc.jfmpc_1007_19.

  22. AlAgha AS, Faris H, Hammo BH, Al-Zoubi AM. Identifyingβ-thalassemia carriers using a data mining approach: Thecase of the Gaza Strip, Palestine. Artif Intell Med 2018; 88:70-83. doi: 10.1016/j.artmed.2018.04.009.

  23. Klaihmon P, Lertthammakiat S, Anurathapan U, PakakasamaS, Sirachainan N, Hongeng S, et al. Activated platelets andleukocyte activations in young patients with β-thalassemia/HbE following bone marrow transplantation. Thromb Res.2018; 169: 8-14. doi: 10.1016/j.thromres.2018.07.007.

  24. Comité Nacional de Hematología, Oncología y MedicinaTransfusional. Anemias microcíticas hipocrómicas: guíade diagnóstico diferencial. Arch Argent Pediatr 2017;115: 83-90.




2020     |     www.medigraphic.com